Potent Farnesyltransferase Inhibitor ABT-100 Abrogates Acute Allograft Rejection

This is the first report that a specific FTI delays the development of acute rejection and supports the strategy of inhibiting Ras to impart immunomodulation. The antirejection and anticarcinogenic effects make FTI℉s a potentially useful adjunct in the antirejection regimens of malignancy-prone organ transplant recipients.